跳至主要内容
临床试验/NCT00453050
NCT00453050已完成1 期

Laser and TLR-Agonist Immunotherapy: A Novel Autologous Melanoma Vaccine Study

University of Oklahoma2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2006年3月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
11
试验地点
2
主要终点
Toxicity and tolerability by CTCAE version 3.0

研究概览

简要总结

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Laser therapy uses light to kill tumor cells. Giving imiquimod together with laser therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects of imiquimod and laser therapy with or without a green dye in treating patients with stage III or stage IV melanoma that has spread to other parts of the skin.

详细描述

OBJECTIVES:

Primary

  • Determine the toxicity of in situ photoimmunotherapy comprising imiquimod and infrared laser therapy with or without indocyanine green in patients with stage III or IV melanoma and cutaneous metastases.
  • Determine the complete systemic and local response rates in patients treated with this regimen.

Secondary

  • Determine the effect of this treatment on immunologic parameters in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Toxicity and tolerability by CTCAE version 3.0

Complete systemic and local response rates at 16 months

次要结局

  • Immunologic parameters

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Imiquimod and Laser Therapy With or Without a Green... | 临床试验